Efficacy of minodronate and denosumab for bone loss in patients with prostate cancer undergoing androgen deprivation therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Minodronic acid (Primary) ; Denosumab
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms PROMADE
- 10 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2016 Status changed from not yet recruiting to recruiting.
- 15 Sep 2015 New trial record